Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesCurrent Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesPrognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemiaDevelopment-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningImmunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingRole of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibitionImpact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseNew markers for minimal residual disease detection in acute lymphoblastic leukemia.Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaProposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemiaThiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsDeep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.The myth of the second remission of acute leukemia in the adult.New considerations in the design of clinical trials for the treatment of acute leukemia.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survivalPersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationPrognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemiaNew approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLEye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
P2860
Q24604581-E18BC88A-91C4-4E0E-BF94-6BA8DA2697B4Q26751269-04394C2C-3B4D-4B4A-843F-036051F9BAD5Q26828511-78A64A50-A8F5-4C8B-82F8-E520FBCFB115Q27006773-712A484C-FD95-4298-8468-CC3F49F42289Q33590468-04146610-4ADE-40D6-A161-BF0EB667F970Q33770150-945222AC-4555-484F-BAAD-D31750E3354AQ34333169-CB104B02-314A-48DC-84E9-6447E301BCBEQ34380489-76B13CF7-1518-4FE1-A696-9444EF9F26B2Q34402494-F90CF894-8FBF-4039-877E-9EEFC9FF391FQ34425875-F2950269-878E-4015-8B6E-4B71B5DBF671Q34532041-CDDBBCAC-214F-495C-A6CE-326912D1EAEFQ34580110-BE81F766-2AE1-4B5F-A475-2A63F8F2A302Q34598903-48D66CC7-C3BD-412E-A601-8404F30EEA4AQ34684038-3EBC9D22-AD17-43EF-AB3F-6E47F121A16FQ35011933-B40EBD77-51AF-4523-A871-DEA1D332918FQ35022780-EC802925-CB04-4430-B50D-86AD215E668AQ35067391-5505220F-A8D7-447E-A9C7-5F42BDCFB9A2Q35106033-4F420228-3864-4969-8A00-6BE55D88E162Q35146312-66154F5B-D551-4CBD-8B5A-CE236A48C8E1Q35976588-CA93C538-6614-431F-9B36-35320D420767Q36069886-B5874D10-5F99-4D65-95AF-C08291BDADBAQ36290737-8C9C6AA9-3AB8-4CDB-B4D4-A3C158F131FFQ36371093-EA101794-1039-4E7E-B6EB-A99B4D930B46Q36393968-CA5A186B-AE78-45BD-AF96-6C077FEF7620Q36461915-02EBEA55-44B6-4F52-B5E9-B2C4ECC78588Q36509641-A6E78A57-B108-4FB6-9ABA-17595D206656Q36513773-65C74308-3655-4A0E-AADF-8C46CC9F2F23Q36619678-706F3D31-6D99-48EC-A033-A01E3B0ED868Q36641721-B6D11864-4857-4BC7-B2A6-5FEBCCD1AF52Q36731636-8BDEC8E9-8F9A-4F14-89AD-34BBE38B279DQ36781786-F66BDA33-41C3-4B25-8E18-33619226552FQ36920398-7D1B4A96-B5C0-4B60-91EA-308DF6129EC2Q37148110-D7FAE1A7-E6DD-4CA3-9F2A-BC2555681F8DQ37344050-FDAF61C6-BA5C-466F-8C7E-BBE74215C258Q37376595-0ABA53C2-9E8F-47FE-B57D-22C588831E8FQ37500642-17D158D4-F51C-4904-871A-E6ECE1F71206Q37577874-0F12D4EF-7750-4AD9-9979-780BFF7E316FQ37685601-73DC4F62-4CDC-4D74-AF31-172452DE9449Q37816933-768B0F6B-B004-4951-9F9E-799D2A096463Q37919867-5D5473A0-9F78-4CEA-8E6A-07D5B153DED4
P2860
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@en
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@nl
type
label
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@en
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@nl
prefLabel
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@en
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@nl
P2093
P356
P1433
P1476
Standardized MRD quantificatio ...... Germany, 18-20 September 2008.
@en
P2093
A Baruchel
A H Goldstone
A K Fielding
A Rambaldi
A Schrauder
A von Stackelberg
E A Macintyre
European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)
P2888
P304
P356
10.1038/LEU.2009.268
P577
2009-12-24T00:00:00Z
P5875
P6179
1026537507